The importance of use of natriuretic peptides in cardiac emergency situations

##plugins.themes.bootstrap3.article.sidebar##

PDF (Русский)
Published: Dec 28, 2017
DOI: https://doi.org/10.30841/2307-5112.6(74).2017.127805
Keywords:
сoronary heart disease, acute coronary syndrome, BNP, NT-proBNP,

##plugins.themes.bootstrap3.article.main##

У. А. Мірзоєв
Central Customs Hospital, Azerbaijan

Abstract

Cardiovascular diseases nowadays remain being the main cause of mortality and morbidity all over the world. It is estimated that in 1990–2020 cardiovascular mortality is going to increase from 28,9% to 36,3% among all the causes of death. The most frequent clinical presentations of cardiac diseases requiring admission to the emergency rooms are chest pains, cardiogenic shocks, shortness of breath, , which could be the symptoms of coronary heart disease, including acute coronary syndromes and heart failure. The natriuretic peptides play a very important role in early diagnosis of different cardiac disorders. An estimation of the level of natriuretic peptides in urgent cardiac situations is very quick, prompt and exact in comparison with other laboratory modalities. Especially use of BNP and NT-proBNP in some different clinical scenarios may help in choosing and directing of treatment schemes of those patients. The rise of NT-proBNP during ischemia in the absence of necrosis is of special importance.

##plugins.themes.bootstrap3.article.details##

How to Cite
Мірзоєв, У. А. (2017). The importance of use of natriuretic peptides in cardiac emergency situations. Family Medicine, (6 (74), 48–51. https://doi.org/10.30841/2307-5112.6(74).2017.127805
Issue
No. 6 (74) (2017)
Section
Cardiology
Copyright (c) 2020 У. А. Мірзоєв

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biography

У. А. Мірзоєв, Central Customs Hospital

Ulvi A. Mirzoyev,

Department of Invasive Cardiology

References

Charles H. Hennekens, MD, DrPH. Increasing burden of cardiovascular disease. Current knowledge and future directions for research on risc factors. Circulation. 1998; 97: 1095–1102. https://doi.org/10.1161/01.CIR.97.11.1095

Cardiovascular diseases (CVDs) [Electronic resource]. – Access: http://www.who.int/mediacentre/factsheets/fs317/en/

Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation. 1993; 88:750–63. https://doi.org/10.1161/01.CIR.88.2.750

Newby LK, Ohman EM, Christenson RH: The role of the troponins and other markers of myocardial necrosis in risk stratification. In Topol E. Acut Coronary Syndromes. Second ed.

New York. Marcel Dekker 2001:329–72.

Akut Koroner Sendromlarэn tanэsэnda yeni biyokimyasal markerlar. Akut Koroner Sendromlar. Tьrk Kardiyoloji Seminerleri. 2001;1(3):20–32.

Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a metaanalysis. J Am Coll Cardiol. 2001;38:478–85. https://doi.org/10.1016/S0735-1097(01)01388-2

James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome. A GUSTO-IV substudy. J Am Coll Cardiol. 2003;41:916–24. https://doi.org/10.1016/S0735-1097(02)02969-8

B-type natriuretic peptide in cardiovascular disease. James A de Lemos, Darren K McGuire, Mark H Drazner. The Lancet .2003:362; 316–322. https://doi.org/10.1016/S0140-6736(03)13976-1

Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988–94. https://doi.org/10.1161/01.HYP.28.6.988

Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurements of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002347:161–167. https://doi.org/10.1056/NEJMoa020233

Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing of cardiac deaths. Lancet. 2002; 359: 1430–32. https://doi.org/10.1016/S0140-6736(02)08358-7

Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet.

; 341:1109–13. https://doi.org/10.1016/0140-6736(93)93126-L

Mallamaci F, Zoccali C, Tripepi G, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001;59:1559–66. https://doi.org/10.1046/j.1523-1755.2001.0590041559.x

Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haemotol. 2000;104:158–63. https://doi.org/10.1159/000046508

Luchner A, Burnett Jc Jr; Juogasaki M, et al. Evaluation of brain natriuretic peptide as a marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000;18:1121–28.

Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288:1252–59. https://doi.org/10.1001/jama.288.10.1252

Mizuno Y, Yoshimura M, Harada E, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000; 86:1036–40. https://doi.org/10.1016/S0002-9149(00)01147-4

Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21–29. https://doi.org/10.1054/jcaf.2001.23355

Richards AM, Crozier IG, Yandle TG, Espinger EA, Ikram H, Nicholls MG. Brain natriuretic factor; regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J. 1993;69:414–17. http://dx.doi.org/10.1136/hrt.69.5.414

Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Card. 1998;31:754–65. https://doi.org/10.1016/S0735-1097(98)00045-X

Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367–74. https://doi.org/10.1067/mhj.2001.113215

Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002; 106:92–99. https://doi.org/10.1161/01.CIR.0000020009.30736.3F

Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995;92:1558–1564. https://doi.org/10.1161/01.CIR.92.6.1558